NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/07/2022
Back to search
Official data from USPTO
IGEG
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
IGEG
ST13
US500000090424617Class
5, 42, 44, 45
Filing
90424617
Registration
6750023
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
23
Latest update
06/10/2022
Trademark type
Word
Nice classes
5, 42, 44, 45
Filing date
12/29/2020
Registration date
06/07/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/07/2022
Last transaction
06/10/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
99
Owner location
London, GB
Examiner
EINSTEIN, MATTHEW T
Law office
M60
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Epsilogen Ltd
Representatives
Susan Piascik Christoff COOLEY LLP
Technical classification
Nice Classes
Class 5Class 42Class 44Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; anti-cancer drugs; anti-cancer preparations; anti-cancer preparations of plant origin; anti-cancer preparations of chemical origin; compounds for treating cancer; tumor suppressing agents; immunostimulants; medicine for the treatment of cancer; diagnostic reagents for medical laboratory use
Class 42
Development of platform technologycancer immunotherapy platforms for manufacturing therapeutics; research and development of pharmaceuticals in the fields of oncologyimmunology and immuno-oncology; research and development of pharmaceuticals for the treatment of cancer and oncological conditions; research and development in the field of cancer therapeuticsoncologynanoparticlestargeted therapies; research and development in the field of recombinant proteins and antibodies for therapeutic and prophylactic use; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new therapeutic proteins and antibodies; development of pharmaceuticalspharmaceutical ingredientsantibodies; scientific study and research in the field of developing personal scientific treatment strategies for patients with diagnosed cancer; pharmaceutical servicesdeveloping tumor targeting platform technologies; scientific research in the nature of scientific collection of specific molecular and genomic data for analytical and clinical purposesfor the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; providing medical and scientific research information in the field of pharmaceuticals and clinical trials in the fields of oncologyimmunology and immuno-oncology; pharmaceutical product development and evaluation services; pharmaceutical research and development; technical research in the field of pharmaceutical studies; conducting early evaluations in the field of new pharmaceuticals; conducting clinical trials for others in the field of pharmaceuticals for the treatment and prevention of cancer; consulting services in the fields of biotechnology and pharmaceutical research; consulting services for others in the field of designplanningimplementation of clinical trials; providing medical and scientific research information in the field of pharmaceuticals and clinical trials
Class 44
Medical screening; medical monitoringtestinginspection and analysis services; medical services relating to the diagnosis and treatment of cancerous diseases; pharmaceutical advisory services; medical laboratory analysis services relating to the treatment of persons; medical laboratory analysis services relating to the diagnosis and treatment of cancerous diseases; providing cancer screening services; medical analysis services for cancer diagnosis and prognosis; RNA or DNA analysis for cancer diagnosis and prognosis; medical services in the field of oncologyimmunology and immuno-oncology; providing advice relating to oncologyimmunology and immuno-oncology; providing on-line information relating to oncologyimmunology and immuno-oncology
Class 45
Licensing of intellectual property rights; licensing of industrial property rights
Publications
History of USPTO decisions and trademark events.
23 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/07/2022
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
04/29/2022
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
04/01/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/15/2022
PUBO
PUBLISHED FOR OPPOSITION
02/15/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/26/2022
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
01/10/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/10/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
01/10/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/10/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
01/10/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/10/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/28/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/28/2021
ALIE
ASSIGNED TO LIE
12/23/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/21/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/28/2021
GNRT
NON-FINAL ACTION E-MAILED
06/28/2021
CNRT
NON-FINAL ACTION WRITTEN
06/28/2021
DOCK
ASSIGNED TO EXAMINER
06/28/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/20/2021
NWAP
NEW APPLICATION ENTERED
01/01/2021
Continuous trademark protection
Get notified about every new filing that threatens IGEG or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.